Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Total Valuation
Haemonetics has a market cap or net worth of $3.16B. The enterprise value is $4.83B.
Market Cap$3.16B
Enterprise Value$4.83B
Share Statistics
Haemonetics has 50,237,465 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50,237,465
Owned by Insiders1.18%
Owned by Institutions0.20%
Financial Efficiency
Haemonetics’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 6.70%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)6.70%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee357.96K
Profits Per Employee32.15K
Employee Count3,657
Asset Turnover0.60
Inventory Turnover1.95
Valuation Ratios
The current PE Ratio of Haemonetics is 36.81. Haemonetics’s PEG ratio is 16.71.
PE Ratio36.81
PS Ratio0.00
PB Ratio4.51
Price to Fair Value4.51
Price to FCF37.48
Price to Operating Cash Flow23.81
PEG Ratio16.71
Income Statement
In the last 12 months, Haemonetics had revenue of 1.31B and earned 117.56M in profits. Earnings per share was 2.32.
Revenue1.31B
Gross Profit691.55M
Operating Income164.88M
Pretax Income151.87M
Net Income117.56M
EBITDA265.58M
Earnings Per Share (EPS)2.32
Cash Flow
In the last 12 months, operating cash flow was 129.25M and capital expenditures -33.32M, giving a free cash flow of 95.93M billion.
Operating Cash Flow129.25M
Free Cash Flow95.93M
Free Cash Flow per Share1.91
Dividends & Yields
Haemonetics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.82
52-Week Price Change-32.36%
50-Day Moving Average63.13
200-Day Moving Average74.30
Relative Strength Index (RSI)54.67
Average Volume (3m)677.74K
Important Dates
Haemonetics upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateFeb 6, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Haemonetics as a current ratio of 2.56, with Debt / Equity ratio of 135.06%
Current Ratio2.56
Quick Ratio1.50
Debt to Market Cap0.19
Net Debt to EBITDA2.37
Interest Coverage Ratio12.67
Taxes
In the past 12 months, Haemonetics has paid 34.31M in taxes.
Income Tax34.31M
Effective Tax Rate0.23
Enterprise Valuation
Haemonetics EV to EBITDA ratio is 18.66, with an EV/FCF ratio of 42.93.
EV to Sales3.79
EV to EBITDA18.66
EV to Free Cash Flow42.93
EV to Operating Cash Flow27.27
Balance Sheet
Haemonetics has $320.85M in cash and marketable securities with $16.13M in debt, giving a net cash position of $903.99M billion.
Cash & Marketable Securities$320.85M
Total Debt$16.13M
Net Cash$903.99M
Net Cash Per Share$17.99
Tangible Book Value Per Share-$0.22
Margins
Gross margin is 52.38%, with operating margin of 12.60%, and net profit margin of 8.98%.
Gross Margin52.38%
Operating Margin12.60%
Pretax Margin11.60%
Net Profit Margin8.98%
EBITDA Margin20.29%
EBIT Margin12.60%
Analyst Forecast
The average price target for Haemonetics is $96.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$96.71
Price Target Upside53.53% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast8.14%
EPS Growth Forecast2.55%